| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/18/2006 | US20060105423 Microorganisms as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors |
| 05/18/2006 | US20060105396 Novel epithelial tissue imaging agent |
| 05/18/2006 | US20060105336 autologous T cell vaccines; multiple sclerosis |
| 05/18/2006 | US20060105333 Method for diagnosis of intestinal-type gastric tumors |
| 05/18/2006 | US20060104996 Methods for producing oocysts |
| 05/18/2006 | US20060104995 Combination of local botulinum toxin and oral triptan drug administration; preventing overuse; reducing pain sensory output |
| 05/18/2006 | US20060104994 Clostridial toxin pharmaceutical composition containing a gelatin fragment |
| 05/18/2006 | US20060104993 Methods and compositions for immunizing against Pseudomonas infection |
| 05/18/2006 | US20060104992 Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising this fragment for detecting, preventing, and treating HIV |
| 05/18/2006 | US20060104991 Methods for constructing antibiotic resistance free vaccines |
| 05/18/2006 | US20060104990 Mixture comprising group B streptococcal peptide for use in generating vaccine and immunoglobulins for diagnosis, prevention and treatment of urinary tract infections |
| 05/18/2006 | US20060104989 Essential novel bacterial polypeptides |
| 05/18/2006 | US20060104988 Vaccines against hiv-1 tat protein to generate neutralizing antibodies |
| 05/18/2006 | US20060104987 Rhesus D antigen encoded by a nucleic acid molecule carrying one or more specific missense mutations used for determining whether a patient that is in need of a blood transfusion needs to be transfused with RhD negative blood |
| 05/18/2006 | US20060104986 Induce immunology response; administering yeast vehicle and antigen |
| 05/18/2006 | US20060104985 Dengue virus infection inhibitor |
| 05/18/2006 | US20060104984 Methods and compositions for use in treating cancer |
| 05/18/2006 | US20060104983 Regions of the protein acting as surface epitopes, capable of providing inhibitors for RLIP76. include antibodies, si- RNA directed against one or more surface epitope regions; screening chemical libraries for compounds that bind ralA binding protein 1 and effect its transport activity |
| 05/18/2006 | US20060104982 Regions of the protein acting as surface epitopes, capable of providing inhibitors for RLIP76. include antibodies, si- RNA directed against one or more surface epitope regions; antiepileptic agent; screening of chemical libraries, compounds that bind ralA binding protein 1 |
| 05/18/2006 | US20060104981 Prophylactic/therapeutic agent for cancer |
| 05/18/2006 | US20060104980 Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes |
| 05/18/2006 | US20060104979 Membrane-type serine protease 1 associated with the etiology of cancer and exhibits activity in the presence of the target substrate Spectrozyme tPA |
| 05/18/2006 | US20060104978 Methods and compositions for PDGF-C activation and inhibition |
| 05/18/2006 | US20060104977 Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells |
| 05/18/2006 | US20060104976 Identification and use of high efficacy vaccine antigens which modulate antigen presenting cells |
| 05/18/2006 | US20060104975 C-type lectin binding molecules, identification and uses thereof |
| 05/18/2006 | US20060104974 CD147 binding molecules as therapeutics |
| 05/18/2006 | US20060104973 Inhibitors of Nogo Receptor (NgR)-p75 binding are used to reduce NgR-p75 binding mediated axon growth inhibition; myelins; for drug screening; cell-free; reducing myelin-mediated inhibition of axon regeneration |
| 05/18/2006 | US20060104972 Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents |
| 05/18/2006 | US20060104971 Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof |
| 05/18/2006 | US20060104946 Method for treating inflammatory bowel disease |
| 05/18/2006 | US20060104945 Enhancement of B cell proliferation by IL-15 |
| 05/18/2006 | US20060104943 Vaccine comprising il-13 and an adjuvant |
| 05/18/2006 | US20060104902 Method of preselection patients for anti-VEGF, anti-HIF-1 or anti-thioredoxin therapy |
| 05/18/2006 | US20060104899 Production and use of novel peptide-based agents for use with bi-specific antibodies |
| 05/18/2006 | DE19608751B4 Verwendung eines Adeno-assoziierten Virus-Vektors zur Steigerung der Immunogenität von Zellen Using an adeno-associated virus vector to enhance the immunogenicity of cells |
| 05/18/2006 | CA2587451A1 Defective influenza virus particles |
| 05/18/2006 | CA2587206A1 Ligands that enhance endogenous compounds |
| 05/18/2006 | CA2587018A1 Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
| 05/18/2006 | CA2586913A1 Targeted innate immunity |
| 05/18/2006 | CA2586856A1 Parathyroid hormone receptor activation and stem and progenitor cell expansion |
| 05/18/2006 | CA2586661A1 Antibodies against tenascin-c |
| 05/18/2006 | CA2586486A1 Leucine-rich repeat (lrr) motif containing proteins |
| 05/18/2006 | CA2586356A1 Anti-properdin antibodies, and methods for making and using same |
| 05/18/2006 | CA2586313A1 Ovr110 antibody compositions and methods of use |
| 05/18/2006 | CA2586283A1 Method of preventive treatment of allergy by mucosal administration of an allergy vaccine |
| 05/18/2006 | CA2582057A1 Compositions against sars-coronavirus and uses thereof |
| 05/17/2006 | EP1657307A1 Oligonucleotides that induce the secretion of GM-CSF |
| 05/17/2006 | EP1657256A2 Compositions and methods for the treatment of tumor |
| 05/17/2006 | EP1657255A1 Novel protein and method for producing the protein |
| 05/17/2006 | EP1657250A1 HLA-A *01-binding T-cell epitope of WT1 |
| 05/17/2006 | EP1657248A2 Vaccine for preventing and treating porcine progressive atrophic rhinitis |
| 05/17/2006 | EP1656952A2 Polymer conjugates of interferon beta-1A and uses thereof |
| 05/17/2006 | EP1656950A1 Immunotoxins directed against CD33 related surface antigens |
| 05/17/2006 | EP1656947A1 Preventive and/or remedy for hematopoietic tumor |
| 05/17/2006 | EP1656391A2 Modified human igf-1r antibodies |
| 05/17/2006 | EP1656123A2 Anti-candida agents for the treatment of prion diseases |
| 05/17/2006 | EP1296711B1 Hpv-e7 for human papilloma virus treatment |
| 05/17/2006 | EP1222300B1 Lentiviral vectors for the preparation of immunotherapeutical compositions |
| 05/17/2006 | EP1214598B1 Screening for inhibitors of "paired helical filaments" |
| 05/17/2006 | EP1200832B1 Annexins and autoantibodies used as markers for lung cancer and oesophageal cancer |
| 05/17/2006 | EP1113818B1 METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN |
| 05/17/2006 | EP1071712B1 Sp22, a fertility-associated protein from sperm and a method for evaluating and affecting male fertility using it |
| 05/17/2006 | EP1035866B1 Mixed lipopeptide micelles for inducing an immune response and their therapeutic uses |
| 05/17/2006 | EP0975668B1 MODIFIED TNFalpha MOLECULES, DNA ENCODING SUCH MODIFIED TNFalpha MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNFalpha MOLECULES AND DNA |
| 05/17/2006 | EP0949333B1 Measles virus mutant antigen and gene encoding the same |
| 05/17/2006 | EP0923941B1 Remedies for myeloma to be used together with nitrogen mustard antitumor agents |
| 05/17/2006 | EP0807124B1 Monoclonal antibody against flt4 receptor tyrosine kinase and its use in diagnosis and therapy |
| 05/17/2006 | EP0796273B1 Variants of human papilloma virus antigens |
| 05/17/2006 | EP0788372B1 Attenuated canine parvovirus vaccine |
| 05/17/2006 | EP0777490B1 Mutant enterotoxin effective as a non-toxic oral adjuvant |
| 05/17/2006 | CN1774447A S. pneumoniae antigens |
| 05/17/2006 | CN1774264A Recombinant herpesvirus of turkeys and use thereof |
| 05/17/2006 | CN1774259A Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
| 05/17/2006 | CN1774255A Sterile immunogenic non-tumorigenic tumor cell compositions and methods |
| 05/17/2006 | CN1774243A Therapeutic compositions |
| 05/17/2006 | CN1772902A One coding gene of rotavirus VP6 protein and its application |
| 05/17/2006 | CN1772892A HIV-1 virus-like particle and its prepn and use |
| 05/17/2006 | CN1772887A Recombinant Newcastle disease LaSota low virulent vaccine strain expressing bird flu virus H5 subtype HA protein |
| 05/17/2006 | CN1772886A Recombinant Newcastle disease LaSota low virulent vaccine strain expressing infectious bursal disease virus VP2 gene |
| 05/17/2006 | CN1772766A Acetylcholinesterase monoclonal antibody related to resisting apoptosis and its use |
| 05/17/2006 | CN1772763A Recombinant water fowl flu rius H7 subtype hemagglutinin antigen and its prepn process and use |
| 05/17/2006 | CN1772306A Group-B type-III Coxsackie virus gene vaccine |
| 05/17/2006 | CN1772305A Group-B type-I Coxsackie virus gene vaccine |
| 05/17/2006 | CN1772304A Group-B type-II Coxsackie virus gene vaccine |
| 05/17/2006 | CN1772303A Nanometer magnetic powder-antibody targeting medicine for magneto thermical threrapy of malignant tumor |
| 05/17/2006 | CN1772302A Heat resistant freeze drying protectant for chicken Newcastle disease live vaccine and its prepn and application |
| 05/17/2006 | CN1772300A Nanometer manetic powder for magnetothermical therapy and anti-CEA antibody target medicine |
| 05/17/2006 | CN1772299A The pIL-4 gene adjuvant for pig vaccine and its prepn process |
| 05/17/2006 | CN1772298A The pIL-6 gene adjuvant for pig vaccine and its prepn process |
| 05/17/2006 | CN1772297A The pIFN-gamma gene adjuvant for pig vaccine and its prepn process |
| 05/17/2006 | CN1772296A New use of prophymosin-alpha |
| 05/17/2006 | CN1772295A Application of cysteamine and its derivative in preparing medicine for raising potency of vaccine antibody |
| 05/17/2006 | CN1772294A Freeze dried duplex live measles and parotitis vaccine and its prepn process |
| 05/17/2006 | CN1772293A Composite hepatitis B virus surface antigen granule containing S1, S2 and S proantigen determinants |
| 05/17/2006 | CN1772001A Application of viscid serratia vaccine in preparing medicine for treating bronchial asthma |
| 05/17/2006 | CN1256148C Use of isatis root extract in immunological adjuvant preparation of DNA vaccine or polypeptide vaccine |
| 05/16/2006 | US7045614 LIM mineralization protein splice variants |
| 05/16/2006 | US7045606 Chelate compound containing ligand with steroids, enzymes, hapten and antibodies |
| 05/16/2006 | US7045605 genetic engineered antibodies, nucleic acids; anticancer agents |